<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00180037</url>
  </required_header>
  <id_info>
    <org_study_id>78052003</org_study_id>
    <nct_id>NCT00180037</nct_id>
  </id_info>
  <brief_title>Coenzyme Q10 as a Symptomatic Treatment in Parkinson's Disease</brief_title>
  <official_title>Multicenter, Placebo Controlled, Randomized, Double-Blinded Study: Coenzyme Q10 Nanodispersion Versus Placebo as Symptomatic Treatment in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsche Parkinson-Vereinigung e.V.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MSE Pharmazeutika GmbH, Bad Homburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to evaluate the symptomatic effects of Coenzyme Q10 nanodispersed
      solution in middle-stage Parkinson's disease (PD) patients (Hoehn&amp;Yahr II to III). The
      treatment phase includes three months period of 300 mg Coenzyme Q10 per day or placebo.

      The primary outcome measure was the combined Unified Parkinson's Disease Rating Scale (UPDRS)
      Part II and III.

      The hypothesis of this study was that Coenzyme Q10 improves the energy status of the diseased
      dopaminergic neuronal cell type and thus producing more dopamine leading to an improvement of
      parkinsonian symptoms in PD patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was designed to evaluate the symptomatic effects of Coenzyme Q10 nanodispersed
      solution in middle-stage non-fluctuating Parkinson's disease (PD) patients (Hoehn&amp;Yahr II to
      III). The treatment phase includes three months period of 300 mg Coenzyme Q10 per day or
      placebo.

      The design of the study was a prospective, randomized, multicenter, double-blind
      placebo-controlled protocol. The intervention includes 100 mg Coenzyme Q10 nanodispersion
      (Nanoquinon solution) tid or matched placebo for three months.

      Participating study centers include Neurological University Outpatient Clinics and
      Neurological Departments of Community-based Hospitals experienced with PD patients.

      The primary outcome measure was the combined Unified Parkinson's Disease Rating Scale (UPDRS)
      Part II and III.

      The hypothesis of this study was that Coenzyme Q10 improves the energy status of the diseased
      dopaminergic neuronal cell type and thus producing more dopamine leading to an improvement of
      parkinsonian symptoms in PD patients.

      Main inclusion criteria:

        -  Parkinson's disease according to the UK Brain Bank criteria

        -  Hoehn &amp; Yahr stadium II until III

        -  Age 40 to 75 years

        -  UPDRS Part III &gt; 15 points

        -  No motor fluctuations or dyskinesias

        -  Stable medication for 4 weeks prior to inclusion

      Main exclusion criteria:

        -  Atypical parkinsonian syndromes

        -  Dyskinesias or motor fluctuations

        -  Coenzyme Q10 treatment in the past

        -  Pregnancy
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Unified Parkinson's Disease Rating Scale (UPDRS) Part II and III</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total UPDRS</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PDQ-39</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF36</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Schwab&amp;England</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery-Asperg</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incontinence</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual behavior</measure>
  </secondary_outcome>
  <enrollment>132</enrollment>
  <condition>Parkinson's Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Coenzyme Q10 Nanodispersion (Nanoquinone)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parkinson's disease according to the UK Brain Bank criteria

          -  Hoehn &amp; Yahr stadium II until III

          -  Male or female

          -  Age 40 to 75 years

          -  UPDRS Part III &gt; 15 points

          -  No motor fluctuations or dyskinesias

          -  Stable parkinsonian condition for 4 weeks prior to inclusion

          -  Outpatients

          -  Patients without or with stable levodopa treatment for 4 weeks prior inclusion

          -  Written informed consent

        Exclusion Criteria:

          -  Atypical or drug-induced parkinsonian syndromes

          -  Dyskinesias or motor fluctuations

          -  Coenzyme Q10 treatment in the past

          -  Pregnancy

          -  Epileptic seizures in the history

          -  Hypothyroidism

          -  Severe medical conditions with interference with study drug

          -  Treatment with CSE inhibitors, thyroidal hormones, antiarrhythmic drugs, warfarin,
             metformin

          -  Treatment or intake of vitamins, magnesium, vitamin E, calcium
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heinz Reichmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Technical University of Dresden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Neurology, University of Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Fachklinik Ichenhausen</name>
      <address>
        <city>Ichenhausen</city>
        <state>Bavaria</state>
        <zip>89335</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Leopoldina Krankenhaus</name>
      <address>
        <city>Schweinfurt</city>
        <state>Bavaria</state>
        <zip>97422</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University of Marburg</name>
      <address>
        <city>Marburg</city>
        <state>Hessen</state>
        <zip>35039</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Deutsche Klinik fuer Diagnostik</name>
      <address>
        <city>Wiesbaden</city>
        <state>Hessen</state>
        <zip>65191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Nuerology, Klinikum Lippe</name>
      <address>
        <city>Lemgo</city>
        <state>Niedersachsen</state>
        <zip>32657</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Klinikum Lueneburg</name>
      <address>
        <city>Lueneburg</city>
        <state>Niedersachsen</state>
        <zip>21339</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Ruhr-University of Bochum</name>
      <address>
        <city>Bochum</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Klinikum Essen-Borbeck</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45359</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Klinik Ambrock</name>
      <address>
        <city>Hagen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>58091</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University of Homburg</name>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Technical University of Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Saxony</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Charite Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.neuro.med.tu-dresden.de</url>
    <description>Homepage of Principle study center</description>
  </link>
  <results_reference>
    <citation>Storch A, Jost WH, Vieregge P, Spiegel J, Greulich W, Durner J, Müller T, Kupsch A, Henningsen H, Oertel WH, Fuchs G, Kuhn W, Niklowitz P, Koch R, Herting B, Reichmann H; German Coenzyme Q(10) Study Group. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol. 2007 Jul;64(7):938-44. Epub 2007 May 14.</citation>
    <PMID>17502459</PMID>
  </results_reference>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>January 16, 2009</last_update_submitted>
  <last_update_submitted_qc>January 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2009</last_update_posted>
  <keyword>Parkinson's disease</keyword>
  <keyword>Coenzyme Q10</keyword>
  <keyword>Treatment</keyword>
  <keyword>Neuroprotection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coenzyme Q10</mesh_term>
    <mesh_term>Ubiquinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

